Maze Therapeutics, Inc. (MAZE) Stock Analysis

Q: What is the MAZE stock price target?

Take-profit $55.28 (+109.1% upside). Prior stop was $24.59.

Q: What are the risks of investing in MAZE?

Concentration risk — Product: MZE829; Quality below floor (1.4 < 4.0); Quality below floor (1.4 < 4.0); Momentum score 3.5/10 — below 4.5 minimum.

Q: Is MAZE overvalued or undervalued?

Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.4). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about MAZE?

12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $64.

Range Bound setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $26.44: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 8.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 11.40; Below-average business quality; Negative price momentum.

Maze Therapeutics is a clinical-stage biopharma using its Compass genetics platform to develop precision medicines for kidney and metabolic diseases. Lead programs MZE829 (APOL1 inhibitor for AMKD, positive Phase 2 proof-of-concept March 2026) and MZE782 (SLC6A19 inhibitor for... Read more

$26.44+109.1% A.UpsideScore 4.7/10#114 of 158 Biotechnology

Stop $24.59Target $55.28(analyst − 13%)A.R:R 8.6:1

Analyst target$63.55+140.3%11 analysts

$55.28our TP

$26.44price

$63.55mean

$110

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: MZE829

Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.4

Mkt Cap$1.4B

EV/EBITDA-6.8

Profit Mgn0.0%

ROE-47.5%

Rev Growth—

Beta—

DividendNone

Rating analysts12

Quality Signals

Piotroski F2/9

Options Flow

P/C11.40bearish

IV88%elevated

Max Pain$60+126.9% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductMZE829
10-K Item 1A: 'highly dependent on the success of our lead programs ... MZE829, our most advanced lead program'

Material Events(8-K, last 90d)

2026-03-25Item 5.02LOW
Neil Kumar (co-founder and CEO of BridgeBio Pharma) appointed as Class I director effective March 27, 2026. Routine board addition; no officer departure.
SEC filing →
2026-02-04Item 1.01MEDIUM
Maze entered Hercules Loan Agreement on February 4, 2026 for senior secured term loan facility up to $200M; $40M initial tranche funded at closing. Maturity February 1, 2031. Secured by first lien on substantially all assets except IP.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.415%0.21

Growth5.015%0.75

Momentum3.510%0.35

Sentiment7.910%0.79

Insider Activity3.410%0.34

Peer Rank3.410%0.34

Technical Setup4.55%0.23

Risk Profile2.95%0.14

Catalyst4.25%0.21

Overall (Σ contributions)4.71

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Volatile — 6.4% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Debt Equity

0.0

Short Interest

5.5

Max Pain Risk

7.0

Days To Cover

8.0

Elevated put/call: 11.40High IV: 88%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

2.6

Value Rank

5.0

Growth Rank

5.0

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Obv

1.0

Ma Position

2.2

Rsi

4.5

Macd

10.0

Volume distribution (falling OBV)Below 200-MA but MA still rising (+9.0%/30d) — pullback in uptrend, not confirmed weakness

GatesMomentum 3.5<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 8.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

49 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $25.08Resistance $29.84

Price Targets

$25

$55

A.Upside+109.1%

A.R:R8.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)

! Momentum score 3.5/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

3/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is MAZE stock a buy right now?

Sell if holding. Engine safety override at $26.44: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 8.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 11.40; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $24.59. Score 4.7/10, moderate confidence.

What is the MAZE stock price target?

Take-profit target: $55.28 (+109.1% upside). Prior stop was $24.59. Stop-loss: $24.59.

What are the risks of investing in MAZE?

Concentration risk — Product: MZE829; Quality below floor (1.4 < 4.0).

Is MAZE overvalued or undervalued?

Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.4). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about MAZE?

12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $64.

What does Maze Therapeutics, Inc. do?Maze Therapeutics is a clinical-stage biopharma using its Compass genetics platform to develop precision medicines for...